Home > Clinical Trials
Check All Search

Saved trials

ACTIVE_NOT_RECRUITING
NCT05704829
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
402 Enrollment(s)
43 Study location(s)
INTERVENTIONAL (PHASE2)
HER2-positive Early Breast Cancer
RECRUITING
NCT04986579
Scalp Cooling in MBC
120 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Breast Cancer


Chemotherapy-induced Alopecia
RECRUITING
NCT07180264
Trastuzumab Deruxtecan in Advanced Breast Cancer
118 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Advanced Breast Cancer
ACTIVE_NOT_RECRUITING
NCT04042701
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
115 Enrollment(s)
30 Study location(s)
INTERVENTIONAL (PHASE1)
Breast Cancer


Non-small Cell Lung Carcinoma
RECRUITING
NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
244 Enrollment(s)
86 Study location(s)
INTERVENTIONAL (PHASE1)
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RECRUITING
NCT04553770
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
88 Enrollment(s)
9 Study location(s)
INTERVENTIONAL (PHASE2)
Early-stage Breast Cancer


Hormone Receptor Positive Breast Carcinoma


Invasive Breast Cancer


Stage II Breast Cancer


Stage IIA Breast Cancer


Stage IIB Breast Cancer


Stage III Breast Cancer
NOT_YET_RECRUITING
NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
65 Enrollment(s)
2 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Metastatic Breast Cancer


HER2 Low Breast Carcinoma


HER2-negative Breast Cancer


Breast Cancer


Breast Cancer Female
RECRUITING
NCT07025148
Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2)
40 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE4)
Coronary Arterial Disease (CAD)


Percutaneous Coronary Intervention (PCI)